Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Subodh Bhatta
Observed name:
Bhatta, Subodh
Institutions:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute,
The Ohio State University Wexner Medical Center,
The Ohio State University
Observed institutions:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute,
The Ohio State University Wexner Medical Center,
The Ohio State University
ORCID:
0000-0003-3804-5370
Observed ORCID:
0000-0003-3804-5370
OpenAlex ID:
A5101301951
Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies
2024
·
Jean Caputo
, Ayush Peddireddi
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
23
PDF
Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study
2025
·
Frederique St-Pierre
, Subodh Bhatta
, et al.
·
Blood Cancer Journal
·
11
PDF
Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era
2025
·
Megan Broughton
, Subodh Bhatta
, et al.
·
Haematologica
·
7
PDF
Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study
2026
·
John Sharp
, Paolo Strati
, et al.
·
Blood Advances
·
6
PDF
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma
2025
·
Sayan Mullick Chowdhury
, Subodh Bhatta
, et al.
·
Journal of Hematology & Oncology
·
4
PDF
Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
2024
·
John Sharp
, Paolo Strati
, et al.
·
Blood
·
3
Evaluation of Characteristics and Outcomes of Patients with Primary and Secondary Plasma Cell Leukemia Treated with Modern Therapies
2024
·
Megan Broughton
, Subodh Bhatta
, et al.
·
Blood
·
2
PDF
Combination Ruxolitinib and Belumosudil Is Tolerable and Induces Responses Despite Treatment Failure As Monotherapies
2024
·
Jean Caputo
, Ayush Peddireddi
, et al.
·
Transplantation and Cellular Therapy
·
2
Impact of baseline osseous involvement on outcomes in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia
2026
·
John Sharp
, Subodh Bhatta
, et al.
·
Blood Neoplasia
·
1
Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
2024
·
Frederique St-Pierre
, Subodh Bhatta
, et al.
·
Blood
·
1
PDF
Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
2024
·
Kaitlin Annunzio
, Subodh Bhatta
, et al.
·
Hematological Oncology
·
1
PDF
Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma
2026
·
John Sharp
, Subodh Bhatta
, et al.
·
Blood Cancer Journal
Genomic Determinants and Clinical Outcomes of Second Primary Hematological Malignancies in Patients with B-cell Cancers
2026
·
Justin Jiang
, Subodh Bhatta
, et al.
·
Transplantation and Cellular Therapy
Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom's Macroglobulinemia (WM)
2024
·
John Sharp
, Subodh Bhatta
, et al.
·
Blood
PDF
Show more works
View as search
Works count:
16
Citation count:
61
H-index:
4
I10-index:
2
Year
Topic
Type